Charles River Laboratories International Inc.
(NYSE:CRL) stock traded higher Wednesday after the contract research organization raised its full-year 2026 financial guidance following second-quarter results that exceeded Wall Street expectations.
The company increased its fiscal 2026 adjusted earnings outlook to $11.15 to $11.45 per share, up from $10.80 to $11.30, compared with the analyst consensus estimate of $11.12.
Charles River also raised its 2026 revenue forecast to $3.879 billion to $3.920 billion, from $3.794 billion to $3.854 billion.
Analysts were expecting $3.85 billion.
